TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03270501
Drug: Golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Axial spondyloarthritis patients who don't have a good treatment response on 2 NSAIDs, will be treated with golimumab. After remission, the therapy will be stopped.~All patients will undergo a ileocoloscopy at baseline and, if positive, at time of remission.
Study: NCT00540709
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00390156
Drug: imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Current dose 400 mg
Study: NCT00618423
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.
Study: NCT03933202
Drug: Cladribine Tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No intervention will be administered as a part of this study. Participants will receive cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
Study: NCT02423603
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patient receive Once a week for three weeks - with one week off treatment
Study: NCT01462695
Drug: Sunitinib Malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT01809314
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Treatment will be given according to standard of care and the Summary of Product Characteristics during the study.
Study: NCT00297479
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 weeks of nicotine patch therapy
Study: NCT02637128
Drug: artesunate-amodiaquine (ASAQ)
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Co-formulated artesunate-amodiaquine (25mg artesunate/67.5mg amodiaquine and 50mg artesunate/135mg amodiaquine tablets) administered once a day for 3 days, according to manufacturer recommended dosing for weight
Study: NCT00606450
Drug: CC-10004
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg CC-10004 taken 1 time per day for 12 weeks
Study: NCT02775500
Drug: apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Comparison of women exposed during pregnancy versus women who are not exposed to apremilast
Study: NCT05008042
Drug: Mecobalamin 5 MG
Normalized name: mecobalamin 5 MG
DrugBank: Mecobalamin (DB03614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Active substance of vitamin B12 is Mecobalamin 5 mg/ml is given intramuscularly
Study: NCT04110275
Drug: Recombinant human tissue-type plasminogen activator derivative
DrugBank: Plasminogen (DB16701)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human tissue-type plasminogen activator derivative(rPA,chemical name: Reteplase,brand name:Ruitongli) 18mg/10ml/stick, provided by AngDe Biotech Pharmaceutical Co.,LIMITED(LTD)
Study: NCT00080262
Drug: Ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution, IV, 40 mg/m2, every 21 days, extended, until PD or discontinued for other reasons.
Study: NCT04110275
Drug: Recombinant human tissue-type plasminogen activator
DrugBank: Plasminogen (DB16701)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human tissue-type plasminogen activator(rt-PA,chemical name:Alteplase,brand name: Actilyse)50mg/stick,provided by Boehringer Ingelheim Pharma Gesellschaft mit beschrankter Haftung(GmbH)\&Co,
Study: NCT01513785
Drug: Rabeprazole and Amoxicillin
Normalized name: rabeprazole, amoxicillin and clarithromycin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin (Zhuhai United Laboratories Co., Zhuhai, China) 1g t.i.d and Rabeprazole (Misato Plant of Eisai Co., Ltd. Japan) 10 mg b.i.d.for 14 days.
Study: NCT01513785
Drug: Amoxicillin and Rabeprazole
Normalized name: rabeprazole, amoxicillin and clarithromycin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin (Zhuhai United Laboratories Co., Zhuhai, China) 1 g t.i.d and Rabeprazole (Misato Plant of Eisai Co., Ltd. Japan) 20 mg b.i.d. for 14 days
Study: NCT03976362
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT03976362
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT03976362
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT03976362
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets
Study: NCT03349177
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg/m2
Study: NCT03349177
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/m2(TC), 100mg/m2(EC-T)
Study: NCT00606450
Drug: CC-10004
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of CC-10004 taken 2 times per day for 12 weeks
Study: NCT01010633
Drug: Vehicle of Loteprednol Etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 to 2 drops of vehicle administered into the study eye, 4 times a day for approximately 14 days.
Study: NCT01010633
Drug: Loteprednol Etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 to 2 drops of study drug administered into the study eye, 4 times a day for approximately 14 days.
Study: NCT01116141
Drug: CH-4051
Normalized name: CHS-828
DrugBank: CHS-828 (DB12980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different doses CH-4051 to be compared
Study: NCT00941382
Drug: Sibutramine-Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sibutramine and metformin, 15 mg per day and 850 mg per day, respectively, in a single tablet, for 180 days
Study: NCT00941382
Drug: Sibutramine
Normalized name: Sibutramine
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg per day for 180 days
Study: NCT00941382
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 850 mg per day for 180 days
Study: NCT00642473
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive erlotinib 150 milligrams (mg) orally daily for 4 weeks.
Study: NCT00642473
Drug: Metronidazole Actavis
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole actavis 1% topical cream will be applied on the face and chest twice daily for 4 weeks.
Study: NCT00697073
Drug: Idebenone
Normalized name: Idebenone
DrugBank: Idebenone (DB09081)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients \> 45 kg/99 lbs: idebenone 2250 mg/day
Study: NCT00446589
Drug: teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: sc injection using a pen like device during every hemodialysis session (thrice a week)
Study: NCT02075970
Drug: Epoetin Alpha
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant study 1: VLBW infant study subjects (weighing 1.0 to 1.5 kg at birth) who are otherwise receiving standard clinical care will be treated with Epoetin Alpha according to a dosing algorithm.~Infant study 2:~Dosing algorithm will be determined by results of Infant Study 1.
Study: NCT00058474
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/m2 IV 5 days a week on days of planned RT
Study: NCT03583866
Drug: Candesartan
Normalized name: Candesartan
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of Candesartan (16mg/day)
Study: NCT01704859
Drug: omega-3 fatty acids (fish oil)
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
Study: NCT01696383
Drug: Travoprost 0.004%/Timolol 0.5% Fixed Combination (DuoTrav)
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One drop self-administered topically to the study eye(s) once daily every evening at 8:00 pm for 12 weeks
Study: NCT01684722
Drug: Omega-3 fatty acids (fish oil)
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
Study: NCT00862992
Drug: Cariprazine 3 mg
Normalized name: cariprazine 3 MG
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00862992
Drug: Cariprazine 6 mg
Normalized name: cariprazine 6 MG
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00862992
Drug: Cariprazine 12.5 mg
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03340129
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3mg per kg every 3 weeks for 4 doses
Study: NCT03340129
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 1mg/kg every 3 weeks for 4 doses, then 480mg every 4 weeks.
Study: NCT03283878
Drug: Cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA for Group 1.~Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA. In addition, two weight based doses of cefazolin will be administered within 24 hours postoperatively for Group 2.
Study: NCT04316013
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled anaesthetic used for maintenance of anaesthesia, dosed as per standard practice
Study: NCT04316013
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous anaesthetic used for induction and maintenance of anaesthesia
Study: NCT04316013
Drug: Lidocaine IV
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5mg/kg loading dose over 20 minutes, followed by an infusion of 2mg/kg/hr up to 4 hours and 1.5mg/kg/hour thereafter. Bolus and maintenance dosages of lidocaine will be per actual body weight and capped at a maximum of 100 kg.
Study: NCT00764751
Drug: Cream vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily application
Study: NCT02841579
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose.
Study: NCT04406623
Drug: SL-172154
Normalized name: vitamin B12
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
Study: NCT01092702
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the first week varenicline will be started at a dose of 0.5 mg once daily for days 1-3; then 0.5 mg twice daily for days 4-7. Target quit date is set at day 8. Varenicline is then continued for weeks 2-12 at a dose of 1 mg twice daily.
Study: NCT00775944
Drug: Offer of voucher for cost-free Nicotine Replacement Therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Offer of voucher for cost-free Nicotine Replacement Therapy over the telephone
Study: NCT00920829
Drug: Naltrexone 50 Mg
Normalized name: naltrexone 50 mg oral tablet
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone 25 or 50 mg per titration schedule
Study: NCT01434459
Drug: Gemcitabine with TheraSphere
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine dose will be escalated and combined with therasphere.
Study: NCT02168075
Drug: 0.25g/kgof 20% mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: When the neurosurgeon starts the drilling of skull, 0.25g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
Study: NCT02168075
Drug: 0.5g/kg of 20% mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: When the neurosurgeon starts the drilling of skull, 0.5g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
Study: NCT02168075
Drug: 1.0g/kg of 20% mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: When the neurosurgeon starts the drilling of skull, 1.0g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
Study: NCT02168075
Drug: 1.5g/kg of 20% mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: When the neurosurgeon starts the drilling of skull,1.5g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
Study: NCT03815825
Drug: IONIS-FB-LRx
Normalized name: IONIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IONIS-FB-LRx at multiple ascending doses, administered subcutaneously every 4 weeks
Study: NCT03991130
Drug: IL-2 and Nivolumab
Normalized name: nivolumab and relatlimab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Course length will be 35 days. Subjects will receive 480 mg IV of nivolumab on day 1 of the cycle. The patient will be admitted to UCSD Jacobs Medical center for standard HD IL-2 which will be administered every 8 hrs for up to 14 doses days 8-12 per institutional practice. The patient will be readmitted days 22-28 for HD IL-2 every 8 hrs for up to 14 doses. Nivolumab 480 mg IV will be administered day 35. Scans for response will occur 4 weeks after day 35 nivolumab dose and response will be determined by RECIST 1.1 to determine if the patient will receive the next course.
Study: NCT01409395
Drug: Metformin and nizatidine
Normalized name: Nizatidine
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will be given a single oral dose of 850 mg of metformin and a single oral dose of 600 mg of nizatidine
Study: NCT01409395
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will be given a single oral dose of 850 mg of metformin
Study: NCT01512056
Drug: AdimFlu-S
Normalized name: S-2
DrugBank: Racepinephrine (DB11124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All enrolled participants will be divided into 3 groups: participants refused to receive vaccination, those receive either one (week 0) or one more booster vaccination (week 0 and week 3). Each dose of vaccine contains 15μg antigen of each virus strain suggested by WHO (A/California/7/2009 (H1N1);A/Perth/16/2009 (H3N2);B/Brisbane/60/2008).
Study: NCT03183778
Drug: Patiromer
Normalized name: Patiromer
DrugBank: Patiromer (DB09263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer dosing will be determined based on fasting potassium concentrations measured at the end of each week, factoring in both the absolute concentration, as well as the rate of change. The baseline dose of patiromer will correspond to the study by Weir et al. (2015); 8.4-g once per day for participants with a baseline serum potassium of greater than or equal to 5.1 mEq/L.
Study: NCT00001428
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00749580
Drug: Switch NRTIs as a Backbone to Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This is a multicenter, pilot randomized, controlled study to evaluate the safety and efficacy of raltegravir in patients switched from a stable boosted PI-based regimen with a NRTI backbone to raltegravir instead of their current NRTIs. A stable boosted PI-based regimen is defined as having a documented HIV RNA \<75 copies/mL for ≥ 3 months prior to study entry, while receiving a boosted PI-based with NRTI backbone. Additionally, patients must not have had HIV RNA ≥ 75 copies/mL during the three months prior to study entry. Approximately 25 patients will be enrolled in the raltegravir treatment arm (Group 1) and approximately 25 patients in the continuation of the current NRTI backbone regimen treatment arm (Group 2). Patients will be randomly assigned 1:1 to a treatment group.
Study: NCT00420667
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03004222
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 ml of 0.5% Bupivacaine
Study: NCT03868124
Drug: Sham surgery + active-comparator eye drops
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham surgery plus postoperative active-comparator eye drops (Timolol Maleate ophthalmic solution, 0.5%)
Study: NCT04060017
Drug: Levoleucovorin Calcium
Normalized name: Levoleucovorin Calcium
DrugBank: Levoleucovorin (DB11596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid leucovorin calcium dosed by weight
Study: NCT03976245
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: injection
Study: NCT03976245
Drug: tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tablet
Study: NCT01507831
Drug: Alirocumab
Normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
Study: NCT03965468
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1. Durvalumab is expected to stimulate the patient's antitumour immune response by binding to PD L1 and shifting the balance toward an antitumour response.
Study: NCT03965468
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
Study: NCT03965468
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2).
Study: NCT03981796
Drug: Placebo matching dostarlimab
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be administered placebo matching dostarlimab
Study: NCT03981796
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will be administered carboplatin
Study: NCT03981796
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will be administered paclitaxel
Study: NCT03965468
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab is a human mAb of the IgG 2 subclass that is directed against CTLA-4 (CD152), a cell surface receptor that is expressed primarily on activated T-cells and acts to inhibit their activation. Tremelimumab completely blocks the interaction of human CTLA-4 with CD80 and CD86, resulting in increased release of cytokines (interleukin-2 and IFN-γ) from human T-cells, peripheral blood mononuclear cells and whole blood.